Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...